Legend Biotech Corporation Share Price

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 17/05/2024 BST 5-day change 1st Jan Change
45.16 USD -2.61% Intraday chart for Legend Biotech Corporation +4.44% -24.95%
Sales 2024 * 538M 42.38B Sales 2025 * 1.06B 83.44B Capitalization 8.23B 648B
Net income 2024 * -313M -24.65B Net income 2025 * -129M -10.16B EV / Sales 2024 * 14.1 x
Net cash position 2024 * 648M 50.99B Net cash position 2025 * 787M 61.97B EV / Sales 2025 * 7.03 x
P/E ratio 2024 *
-46.2 x
P/E ratio 2025 *
-101 x
Employees 2,000
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.8%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.61%
1 week+4.44%
Current month+3.25%
1 month-4.16%
3 months-22.29%
6 months-30.05%
Current year-24.95%
More quotes
1 week
42.11
Extreme 42.11
46.89
1 month
42.08
Extreme 42.075
48.55
Current year
42.08
Extreme 42.075
70.13
1 year
42.08
Extreme 42.075
77.32
3 years
30.76
Extreme 30.755
77.32
5 years
23.41
Extreme 23.41
77.32
10 years
23.41
Extreme 23.41
77.32
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 30/06/19
Director of Finance/CFO 53 31/08/19
Chief Tech/Sci/R&D Officer - 30/04/18
Members of the board TitleAgeSince
Chief Executive Officer 51 30/06/19
Director/Board Member 67 30/04/20
Director/Board Member 74 22/11/20
More insiders
Date Price Change Volume
17/05/24 45.16 -2.61% 566,508
16/05/24 46.37 +1.33% 1,049,636
15/05/24 45.76 +3.11% 1,052,434
14/05/24 44.38 +3.28% 1,110,387
13/05/24 42.97 -0.62% 1,328,091

Delayed Quote Nasdaq, May 17, 2024 at 09:00 pm

More quotes
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
45.16 USD
Average target price
85.2 USD
Spread / Average Target
+88.66%
Consensus